Verastem wins first FDA approval for ovarian cancer therapy
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), a rare form of a slow ...
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), a rare form of a slow ...
